Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1075-1080

  Voce, Pasquale ^a   D'Agostino, Maria ^b   Moretti, Sonia ^a   Sponziello, Marialuisa ^c   Rhoden, Kerry ^d   Calcinaro, Filippo ^a   Tamburrano, Giulia ^c   Tallini, Giovanni ^d   Puxeddu, Efisio ^a   Filetti, Sebastiano ^c   Russo, Diego ^b   Durante, Cosimo ^c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Akt; ERK; Sunitinib; Vascular endothelial growth factor

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; MICROVASCULATURE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEK293 CELLS; HUMANS; INDOLES; MICE; MICE, INBRED NOD; MICE, SCID; MICROVESSELS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053151669     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1422     Document Type: Article

References (20)

1. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 10: 1011-1021, 2003.
2. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 1: 327-337, 2003. (Pubitemid 36109749)
3. Le Tourneau C, Raymond E and Faivre S: Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 2: 341-348, 2007. (Pubitemid 46881462)
4. Patyna S, Laird AD, Mendel DB, et al: SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 7: 1774-1782, 2006. (Pubitemid 44323245)
5. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
6. Rini BI and Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000, 2009.
7. Gounder MM and Maki RG: Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemoter Pharmacol 67 (Suppl 1): S25-S43, 2011.
8. Zhang J, Yang PL and Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39, 2009.
9. Stommel JM, Kimmelman AC, Ying H, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290, 2007. (Pubitemid 47574858)
10. Sponziello ML, Bruno R, Durante C, et al: Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm Metab Res 43: 22-25, 2011.
11. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
12. Mena CA, Pulido EG and Guillen-Ponce C: Understanding the molecular-based mechanism of action of the thyrosine kinase inhibitor: sunitinib. Anticancer Drugs 21 (Suppl 1): S3-S11, 2010.
13. Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S and Trent JC: Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemoter Pharmacol 67 (Suppl 1): S15-S24, 2011.
14. Powles T, Chowdhury S, Jones R, et al: Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 104: 741-745, 2011.
15. Valent P: Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, mana-gement, and therapy of the disease. Br J Haematol 142: 361-378, 2008.
16. Rini BI, Wilding G, Hudes G, et al: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462-4468, 2009.
17. Hammers HJ, Verheul HM, Salumbides B, et al: Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 6: 1525-1535, 2010.
18. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006. (Pubitemid 44301348)
19. O'Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508, 2006. (Pubitemid 43259931)
20. Faivre S, Demetri G, Sargent W and Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734-745, 2007. (Pubitemid 47338181)